How to buy Inhibikase Therapeutics stock (Inhibikase Therapeutics)

Inhibikase Therapeutics is a biotechnology business based in the US. Inhibikase Therapeutics shares (IKT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $3.20 – a decrease of 6.98% over the previous week. Inhibikase Therapeutics employs 8 staff and has a trailing 12-month revenue of around $79,570.

Our top picks for where to buy Inhibikase Therapeutics Inc stock

Buy Inhibikase Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Inhibikase Therapeutics stock price (NASDAQ: IKT)

Use our graph to track the performance of IKT stocks over time.

Inhibikase Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$3.20
52-week range	$1.12 - $4.20
50-day moving average more info button	$2.50
200-day moving average more info button	$1.83
Wall St. target price	$7.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-3.12

Is it a good time to buy Inhibikase Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Inhibikase Therapeutics price performance over time

Historical closes compared with the close of $3.16 from 2024-12-19

1 week (2024-12-13)	-8.14%
1 month (2024-11-22)	36.80%
3 months (2024-09-20)	163.33%
6 months (2024-06-21)	125.71%

1 year (2023-12-21)	150.79%
2 years (2022-12-21)	9.72%
3 years (2021-12-21)	9.84
5 years (2019-12-18)	N/A

Inhibikase Therapeutics financials

Revenue TTM	$79,570
Gross profit TTM	$-8,258,499
Return on assets TTM	-76.21%
Return on equity TTM	-149.69%
Profit margin	0%
Book value	$1.78
Market Capitalization more info button	$245.3 million

TTM: trailing 12 months

Inhibikase Therapeutics share dividends

We're not expecting Inhibikase Therapeutics to pay a dividend over the next 12 months.

You may also wish to consider:

Have Inhibikase Therapeutics's shares ever split?

Inhibikase Therapeutics's shares were split on a 1:6 basis on 29 June 2023 . So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Inhibikase Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Inhibikase Therapeutics shares which in turn could have impacted Inhibikase Therapeutics's share price.

Inhibikase Therapeutics share price volatility

Over the last 12 months, Inhibikase Therapeutics's shares have ranged in value from as little as $1.12 up to $4.2. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Inhibikase Therapeutics's is 1.118. This would suggest that Inhibikase Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

To put Inhibikase Therapeutics's beta into context you can compare it against those of similar companies.

• Regeneron Pharmaceuticals (REGN.US): 0.142
• Biogen (BIIB.US): -0.061
• Alector (ALEC.US): 0.657

Inhibikase Therapeutics overview

Inhibikase Therapeutics, Inc. , a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd.

Frequently asked questions

null
What percentage of Inhibikase Therapeutics is owned by insiders or institutions?
Currently 10.463% of Inhibikase Therapeutics shares are held by insiders and 11.623% by institutions. How many people work for Inhibikase Therapeutics?
Latest data suggests 8 work at Inhibikase Therapeutics. When does the fiscal year end for Inhibikase Therapeutics?
Inhibikase Therapeutics's fiscal year ends in December. Where is Inhibikase Therapeutics based?
Inhibikase Therapeutics's address is: 3350 Riverwood Parkway SE, Atlanta, GA, United States, 30339 What is Inhibikase Therapeutics's ISIN number?
Inhibikase Therapeutics's international securities identification number is: US45719W1062